Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sosei, Takeda Seal Multi-Target Collaboration Deal
August 6, 2019
- AstraZeneca’s Japan Sales Surge 28% in H1 on Oncology Growth
August 6, 2019
- Rakuten Ups Its Stake in Rakuten Medical to 22.6%
August 5, 2019
- Gene Panel Testing Should Be Done “at an Early Stage”: Chugai Official
August 5, 2019
- Daiichi Sankyo Upping Pitches for Tarlige in May: Impact Track Survey
August 2, 2019
- Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO
August 2, 2019
- Kyowa Kirin Nets Double-Digit Growth in 1st Half, Keeps Full-Year Guidance for Nesp
August 2, 2019
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
- Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
- Eisai Posts Flat Revenue in Q1, Lenvima Sales Double
August 1, 2019
- Daiichi Sankyo Logs Double-Digit Growth in Q1 as Olmetec Cliff Tails Off; Profit Zooms on AZ Deal, Asset Sale
August 1, 2019
- Medipal to Buy Back Shares from Takeda
August 1, 2019
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- US FDA Accepts Sunovion’s Dasotraline Submission for Binge Eating Disorder
August 1, 2019
- Oita Univ. Spinout, Daiichi Sankyo Tie Up on Peptide Mimetics Research
July 31, 2019
- Crushing Defeat or Sign of Hope? Analyst, KOL Give Mixed Views for CheckMate-227
July 31, 2019
- Astellas Secures Q1 Growth as Xtandi, Betanis Offset LOE Impact
July 31, 2019
- Eisai Halts Epilepsy Drug Studies after Death in Japan PI
July 31, 2019
- Pfizer Japan Seeks to Expand Bosulif Label into 1st-Line CML
July 31, 2019
- Otsuka Ups Half-Year Outlook on Bullish Jynarque
July 31, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…